KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Inventory (2016 - 2025)

Vertex Pharmaceuticals has reported Inventory over the past 15 years, most recently at $1.7 billion for Q4 2025.

  • Quarterly results put Inventory at $1.7 billion for Q4 2025, up 39.94% from a year ago — trailing twelve months through Dec 2025 was $1.7 billion (up 39.94% YoY), and the annual figure for FY2025 was $1.7 billion, up 39.94%.
  • Inventory for Q4 2025 was $1.7 billion at Vertex Pharmaceuticals, up from $1.6 billion in the prior quarter.
  • Over the last five years, Inventory for VRTX hit a ceiling of $1.7 billion in Q4 2025 and a floor of $298.9 million in Q1 2021.
  • Median Inventory over the past 5 years was $646.1 million (2023), compared with a mean of $780.7 million.
  • Biggest five-year swings in Inventory: rose 13.4% in 2022 and later surged 77.41% in 2023.
  • Vertex Pharmaceuticals' Inventory stood at $353.1 million in 2021, then surged by 30.44% to $460.6 million in 2022, then soared by 60.4% to $738.8 million in 2023, then skyrocketed by 63.16% to $1.2 billion in 2024, then surged by 39.94% to $1.7 billion in 2025.
  • The last three reported values for Inventory were $1.7 billion (Q4 2025), $1.6 billion (Q3 2025), and $1.5 billion (Q2 2025) per Business Quant data.